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Objectives This study sought to evaluate the impact of age on outcomes in patients with moderate- and high-risk non–ST-
segment elevation acute coronary syndrome (NSTE-ACS) enrolled in the ACUITY (Acute Catheterization and Ur-
gent Intervention Triage Strategy) trial.
Background Aging-associated changes in physiology and metabolism may alter the risk and benefit of therapeutic strategies
from that observed in younger people.
Methods We performed a pre-specified analysis of 30-day and 1-year outcomes in 4 age groups, overall and among those
undergoing percutaneous coronary intervention (PCI).
Results Of 13,819 patients in the ACUITY trial, 3,655 (26.4%) were 55 years of age, 3,940 (28.5%) were 55 to 64
years of age, 3,783 (27.4%) were 65 to 74 years of age, and 2,441 (17.7%) were 75 years of age. Older pa-
tients had more cardiovascular risk factors and had a higher acuity at presentation. Patients age 75 years
treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared
with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset. The number
needed to treat with bivalirudin alone to avoid 1 major bleeding event was lower in this age group (23 overall
and 16 for PCI-treated patients) than in any other.
Conclusions Ischemic and bleeding complications after NSTE-ACS increase with age. Although ischemic event rates are not
statistically different with either bivalirudin alone or a heparin plus glycoprotein IIb/IIIa inhibitor, bleeding com-
plications are significantly less frequent with bivalirudin alone. Because of the substantial risk of bleeding in pa-
tients age 75 years, the number needed to treat to avoid 1 major bleeding event using bivalirudin alone was
the lowest in the elderly group, especially among those undergoing PCI. (Comparison of Angiomax Versus Hepa-
rin in Acute Coronary Syndromes [ACS]; NCT00093158) (J Am Coll Cardiol 2009;53:1021–30) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.021i
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Age and Antithrombotic Therapy in NSTE-ACS March 24, 2009:1021–30Older adults (age75 years) with
non–ST-segment elevation acute
coronary syndromes (NSTE-ACS)
are prevalent among the treated
population and are at particularly
high risk for recurrent throm-
botic events and death (1–3).
Antithrombotic therapy plays an
important role in reducing isch-
emic events in these patients (4–
9), yet paradoxically they are also
at relatively higher risk of bleed-
ing with antithrombotic agents
and catheter-based interventions
(10,11). Major bleeding com-
pounds adverse outcomes, and
independently increases the risk
of death and rehospitalization at
30 days and 6 months (12–15).
Several studies have shown that bivalirudin, a direct
hrombin inhibitor, has similar efficacy in reducing ischemic
vents with a superior bleeding profile compared with
tandard therapy with a heparin plus glycoprotein (GP)
Ib/IIIa inhibitors in patients undergoing elective percuta-
eous coronary intervention (PCI) or with an initial invasive
trategy after moderate- to high-risk NSTE-ACS (16–20).
ased on these studies, bivalirudin has been given a class IB
ecommendation in the 2007 American College of Cardi-
logy/American Heart Association (ACC/AHA) NSTE-
CS guidelines when an invasive strategy is planned (9). An
ntithrombotic strategy with relatively lower rates of bleed-
ng and with preserved ischemic efficacy would be particu-
arly desirable for the elderly population, in whom rates of
schemic and bleeding complications are higher than those
bserved in their younger counterparts.
Therefore, using data from the ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy) trial,
e investigated outcomes across age groups (55, 55 to 64,
5 to 74, and 75 years) in moderate- and high-risk
STE-ACS patients who underwent an early invasive
trategy. Outcomes and the number needed to treat (NNT)
re shown in those randomized to bivalirudin alone or
noxaparin or unfractionated heparin (UFH) plus GP IIb/
ollack is a consultant for Sanofi-Aventis, Schering-Plough, The Medicines Com-
any, and Bristol-Myers Squibb. Dr. Hoekstra is a consultant for The Medicines
ompany, Heartscape, Schering-Plough, and Sanofi-Aventis. Dr. Gersh is a consul-
ant and/or member of the Data Safety Monitoring Board for AstraZeneca,
ristol-Myers Squibb, Abbott Laboratories, Boston Scientific, and Novartis, and is a
hareholder of CV Therapeutics. Dr. Stone has received research grants from The
edicines Company and honoraria from Eli Lilly. Dr. Ohman is a consultant for The
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cope, and Abioed; has received research grants from Sanofi-Aventis, Bristol-Myers
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Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
CABG  coronary artery
bypass graft
GP  glycoprotein
MI  myocardial infarction
NNT  number needed
to treat
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome(s)
PCI  percutaneous
coronary intervention
UFH  unfractionated
heparin1
Manuscript received September 30, 2008; revised manuscript received December 9,
008, accepted December 16, 2008.IIa inhibitors overall, among patients receiving a PCI, and
n those without excess dosing.
ethods
he ACUITY trial and population. The rationale, design,
nd primary results of the ACUITY trial have been previ-
usly reported (19 –21). The ACUITY trial enrolled
STE-ACS patients at moderate or high risk for adverse
linical outcomes at 30 days. Patients presenting with
schemic symptoms of at least 10 min duration within the
revious 24 h were eligible for enrollment if they met one of
he following criteria: new ST-segment depression or tran-
ient elevation of at least 1 mm; elevations in the troponin
, troponin T, or creatine kinase-MB levels; known coro-
ary artery disease; or all 4 other variables for predicting
hrombolysis In Myocardial Infarction risk scores for un-
table angina (22). Patients were excluded if they had
T-segment elevation or shock, bleeding episodes within
he prior 2 weeks, thrombocytopenia, creatinine clearance
30 ml/min, or recent administration of abciximab, warfa-
in, fondaparinux, fibrinolytic agents, bivalirudin, or 2 or
ore doses of low molecular weight heparin.
Patients were randomized in an open-label fashion to 1 of
he following 3 antithrombotic regimens: a heparin (either
noxaparin or UFH) plus a GP IIb/IIIa inhibitor, bivaliru-
in plus a GP IIb/IIIa inhibitor, or bivalirudin alone.
atients assigned to a GP IIb/IIIa inhibitor arm were
urther randomized in a 2  2 factorial design to either
pstream or catheterization laboratory initiation of GP
Ib/IIIa inhibitor. Coronary angiography was required per
rotocol within 72 h of randomization, with subsequent
riage to treatment with PCI, coronary artery bypass graft
CABG) surgery, or medical management per physician
iscretion. Aspirin (300 to 325 mg orally or 250 to 500 mg
ntravenously) was administered before angiography and
aily during the index hospitalization. Dosing and timing of
lopidogrel were left to the discretion of the investigators,
ut 300 mg was required per protocol no later than 2 h after
CI. Clopidogrel 75 mg daily was recommended for 1 year
n all patients after PCI and aspirin 75 to 325 mg daily
ndefinitely.
The ACUITY trial was powered for 3 primary 30-day
nd points: 1) composite ischemia, defined as death from
ny cause, nonfatal myocardial infarction (MI), or un-
lanned revascularization for ischemia; 2) non–CABG-
elated major bleeding, defined as intracranial, intraocular,
r retroperitoneal bleeding, access site hemorrhage requir-
ng intervention, hematoma 5 cm diameter, reduction in
emoglobin of 4 g/dl without or 3 g/dl with an overt
leeding source, reoperation for bleeding, or blood product
ransfusion; and 3) net adverse clinical outcome (composite
schemia and non-CABG major bleeding outcomes).
nalysis population. The ACUITY trial age-subgroup
nalysis was pre-specified. All ACUITY trial patients (n 
3,819) were included and stratified into 4 progressively
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March 24, 2009:1021–30 Age and Antithrombotic Therapy in NSTE-ACSlder age groups: 55, 55 to 64, 65 to 74, and 75 years.
utcomes are displayed overall (n  13,819) and among
hose undergoing PCI (n  7,789). Sensitivity analyses
ere also performed after excluding patients with excess
osing of antithrombotic therapies (n  436). Specifically,
atients with creatinine clearance 50 ml/min receiving
ore than the recommended dose of eptifibatide (n  415)
nd those with creatinine clearance 30 ml/min receiving
ore than the protocol recommended dose of enoxaparin
n  27) were excluded. Six patients overall received an
xcess dose of both drugs. In the PCI cohort, there were 281
atients who met the excess dose criteria. Of these patients,
received more than the recommended low molecular
eight heparin dose, and 274 received more than the
ecommended eptifibatide dose. Only 1 patient had received
n excess dose of both drugs.
tatistical analysis. Counts and percentages for demo-
raphic characteristics, medical history, procedures, and
oncomitant medications are shown by age group. The
ean, median, and standard deviation are provided for
ontinuous variables. Baseline characteristics were compared
cross age groups using the nonparametric Kruskal-Wallis
est for continuous variables and Mantel-Haenszel chi-
quare test for categorical variables. All event rates are
ercentages of patients who experienced the outcome.
tatistical comparisons of these event rates across age groups
ere performed using Mantel-Haenszel chi-square tests.
aseline Characteristics and Medical History by Age Category
Table 1 Baseline Characteristics and Medical History by Age C
Age <55 yrs
(N  3,655)
Age 5
(N
Weight (kg)* 89.9 (78.0, 102.0) 86.0 (
Female sex 853/3,655 (23.3) 1,028
Race
White 3,069/3,650 (84.1) 3,437
Black 295/3,650 (8.1) 210
Hispanic 183/3,650 (5.0) 205
Other 103/3,650 (2.8) 87
ECG changes† 1,103/3,654 (30.2) 1,330
Creatinine clearance (ml/min)* 117.43 (97.7, 142.2) 95.47 (
Creatinine clearance 50 ml/min 51/3,430 (1.5) 115
Positive biomarker before enrollment‡ 2,003/3,393 (59.0) 2128
HGB baseline (g/dl)*§ 14.60 (13.5, 15.5) 14.20 (
HCT baseline (%)*§ 42.70 (39.7, 45.2) 41.80 (
Baseline platelet (103 cells/mm3)* 241.0 (202.0, 286.0) 228.0 (
History
Hypertension 1,922/3,635 (52.9) 2,577
Hyperlipidemia 1,800/3,567 (50.5) 2,231
Family history of CAD 2,008/3,295 (60.9) 1,883
CABG 369/3,646 (10.1) 670
PCI 1,399/3,639 (38.4) 1,564
MI 1,082/3,588 (30.2) 1,182
TIA or stroke 107/3,622 (3.0) 206
Current smoker 1,866/3,621 (51.5) 1,309
alues are n/N (%). *Median (25th, 75th percentile). †ST-segment deviation. ‡Elevated creatine
CABG  coronary artery bypass graft; CAD  coronary artery disease; ECG  electrocardiogram; HC
ntervention; TIA  transient ischemic attack.The primary outcomes in those randomized to bivalirudin
r a heparin plus a GP IIb/IIIa inhibitor are shown by age
verall and in the subgroup undergoing PCI. The differ-
nces between these arms in terms of NNT to prevent 1
ajor bleeding event are also shown. The NNT is derived
y dividing the absolute event rate difference between the
eparin plus GP IIb/IIIa inhibitor arm (event rate A) and
he bivalirudin alone arm (event rate B) into the number 1
1/[event rate A  event rate B]).
The SAS statistical software package (SAS Institute Inc.,
ary, North Carolina) was used for all analyses. A p value of
.05 was used to declare statistical significance, bearing in
ind the exploratory nature of these analyses.
esults
aseline Characteristics
f the 13,819 patients enrolled in the ACUITY trial, 3,655
26.4%) were55 years of age, 3,940 (28.5%) were between
5 and 64 years of age, 3,783 (27.4%) were between 65 and
4 years of age, and 2,441 (17.7%) were 75 years of age.
he median age in each age category was 49.0, 60.0, 69.0,
nd 79.0 years, respectively. Older patients comprised a
icker group who were more often female, weighed less, and
ad more hypertension, prior cerebral vascular disease, renal
nsufficiency (creatinine clearance 50 ml/min), and prior
ABG (Table 1). They also had slightly lower baseline
ory
4 yrs
40)
Age 65 to 74 yrs
(N  3,783)
Age >75 yrs
(N  2,441) p Value
98.0) 82.0 (72.0, 92.0) 75.0 (67.0, 85.0) 0.0001
(26.1) 1,246/3,783 (32.9) 1,030/2,441 (42.2) 0.0001
0.0001
(87.3) 3,452/3,779 (91.3) 2,269/2,440 (93.0)
(5.3) 128/3,779 (3.4) 59/2,440 (2.4)
(5.2) 149/3,779 (3.9) 96/2,440 (3.9)
(2.2) 50/3,779 (1.3) 16/2,440 (0.7)
(33.8) 1,405/3,775 (37.2) 987/2,437 (40.5) 0.0001
114.0) 75.32 (61.9, 90.6) 56.09 (45.2, 68.0) 0.0001
(3.1) 370/3,540 (10.5) 808/2,278 (35.5) 0.0001
(58.8) 2064/3,458 (59.7) 1357/2,244 (60.5) 0.60
15.2) 13.90 (12.8, 14.9) 13.40 (12.3, 14.4) 0.0001
44.4) 41.00 (37.9, 43.9) 39.50 (36.5, 42.3) 0.0001
, 269.0) 221.0 (185.0, 264.0) 216.0 (180.0, 256.0) 0.0001
(65.7) 2,811/3,763 (74.7) 1,902/2,428 (78.3) 0.0001
(57.7) 2,337/3,714 (62.9) 1,379/2,392 (57.7) 0.0001
(54.6) 1,534/3,146 (48.8) 796/1,974 (40.3) 0.0001
(17.1) 833/3,765 (22.1) 593/2,434 (24.4) 0.0001
(40.1) 1,438/3,732 (38.5) 919/2,407 (38.2) 0.36
(30.6) 1,158/3,672 (31.5) 800/2,366 (33.8) 0.02
(5.3) 261/3,720 (7.0) 229/2,391 (9.6) 0.0001
(33.7) 607/3,675 (16.5) 161/2,371 (6.8) 0.0001
B or troponin. §Converted to standard.ateg
5 to 6
 3,9
75.4,
/3,940
/3,939
/3,939
/3,939
/3,939
/3,938
78.3,
/3,691
/3,617
13.2,
38.9,
193.0
/3,921
/3,867
/3,451
/3,929
/3,905
/3,857
/3,894
/3,890
kinase-M
T  hematocrit; HGB  hemoglobin; MI  myocardial infarction; PCI  percutaneous coronary
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Age and Antithrombotic Therapy in NSTE-ACS March 24, 2009:1021–30ematocrit and platelet counts (Table 1). Older patients had
onger hospital stays, but a similar prevalence of left ventricular
ysfunction (ejection fraction 30%). Procedural characteris-
ics were similar across the age subgroups (Table 2).
ssociation Between Age and Outcomes
ombined ischemic end point for overall and PCI
roups. Ischemic events increase with age (Table 3). The
ates of composite ischemia in the age groups overall were
ardiac Procedures and Concomitant Medications During Hospitali
Table 2 Cardiac Procedures and Concomitant Medications Dur
Age <55 yrs
(N  3,655)
Age 5
(N 
Received angiography 3,629/3,655 (99.3) 3,903/3
Left ventricular ejection fraction (%)* 55.0 (50.0, 63.0) 55.0 (4
Number of attempted vessels
0 1/2,051 (0.0) 1/2
1 1,733/2,051 (84.5) 1,864/2
2 289/2,051 (14.1) 332/2
3 28/2,051 (1.4) 41/2
PCI 2,052/3,655 (56.1) 2,240/3
CABG 273/3,655 (7.5) 479/3
Time to angiography (h)* 4.8 (1.8, 19.4) 4.6 (1
Time from randomization to PCI (h)* 5.1 (2.1, 20.2) 4.9 (2
Time to CABG (h)* 71.3 (29.4, 135.6) 70.1 (2
Length of hospitalization (days)* 2 (2, 4) 3 (2
Aspirin before angiography/PCI 3,544/3,610 (98.2) 3,800/3
Thienopyridine before angiography/PCI 2,304/3,605 (63.9) 2,464/3
alues are n/N (%). *Median (25th, 75th percentile).
Abbreviations as in Table 1.
vent Rates (%) in Each Treatment per Age Category at 30 Days a
Table 3 Event Rates (%) in Each Treatment per Age Category a
Age <55 yrs
N  3,655 (%)
Age
N
Bivalirudin Heparin/GPI Bivalirud
30-day outcomes
Net clinical outcomes 6.4 7.7 9.3
Composite ischemia 5.0 5.0 7.8
Death from any cause 0.3 0.3 1.0
Myocardial infarction 4.0 3.7 5.6
Unplanned revascularization 1.4 1.7 3.0
Non-CABG major bleeding 1.7 3.2* 2.2
Intracranial 0.1 0 0.1
Retroperitoneal 0.2 0.5 0.1
Access site 0.2 0.2 0.6
Hemoglobin decrease 3 g/dl 0.6 1.0 0.8
Hemoglobin decrease 4 g/dl 0.3 0.5 0.8
Blood transfusion 0.7 1.0 0.7
Reoperation for bleeding 0 0 0.2
Non-CABG minor bleeding 10.9 16.9* 12.0
TIMI major bleeding 0.9 1.0 0.3
TIMI minor bleeding 2.7 3.8 2.4
1-year outcomes
Composite ischemia 12.4 12.1 15.3
Mortality 1.3 0.7 2.3p  0.05. Net clinical outcome  composite ischemia and non-CABG major bleeding outcomes.
CABG  coronary artery bypass graft; GPI  glycoprotein inhibitor; TIMI  Thrombolysis In Myocardial.7%, 7.3%, 8.0%, and 10.7%, for age 55, 55 to 64, 65 to
4, and 75 years, respectively. Mortality and composite
schemic outcomes at 30 days were not statistically different
n patients randomized to bivalirudin alone or randomized
o heparin with GP IIb/IIIa inhibitors across all age
ategories. Particularly, for patients older than 75 years of
ge the rates of composite ischemic outcomes, death, MI,
nd unplanned revascularization at 30 days for the 2
ifferent antithrombotic strategies (bivalirudin alone vs.
n
ospitalization
4 yrs
0)
Age 65 to 74 yrs
(N  3,783)
Age >75 yrs
(N  2,441) p Value
(99.1) 3,740/3,783 (98.9) 2,402/2,441 (98.4) 0.008
3.0) 55.0 (47.0, 65.0) 55.0 (45.0, 62.0) 0.0005
0.97
(0.0) 1/2,121 (0.0) 1/1,375 (0.1)
(83.3) 1,763/2,121 (83.1) 1,145/1,375 (83.3)
(14.8) 323/2,121 (15.2) 205/1,375 (14.9)
(1.8) 34/2,121 (1.6) 24/1,375 (1.7)
(56.9) 2,121/3,783 (56.1) 1,376/2,441 (56.4)
(12.2) 501/3,783 (13.2) 286/2,441 (11.7)
.0) 4.6 (1.6, 20.5) 4.6 (1.7, 20.8) 0.91
.6) 4.9 (2.0, 21.3) 5.3 (2.1, 22.2) 0.36
39.4) 71.5 (39.6, 159.0) 64.6 (26.8, 128.0) 0.14
3 (2, 7) 4 (2, 8) 0.0001
(97.8) 3,631/3,725 (97.5) 2,340/2,380 (98.3) 0.08
(63.5) 2,378/3,718 (64.0) 1,531/2,376 (64.4) 0.91
Year for All Patients
Days and 1 Year for All Patients
64 yrs
40 (%)
Age 65 to 74 yrs
N  3,783 (%)
Age >75 yrs
N  2,441 (%)
Heparin/GPI Bivalirudin Heparin/GPI Bivalirudin Heparin/GPI
10.5 10.8 13.4* 16.4 17.1
6.7 8.2 8.7 11.7 9.6
1.2 1.9 1.5 4.2 3.0
4.6 5.3 6.0 7.4 5.8
1.8 2.9 3.3 2.2 2.4
4.6* 3.6 6.4* 5.8 10.1*
0 0.1 0.1 0 0.2
0.5* 0.1 0.4 0.4 0.7
2.2* 1.1 2.7* 0.9 4.2*
1.9* 1.1 2.6* 1.8 3.9*
0.6 0.9 1.3 1.0 1.1
2.1* 2.2 2.9 3.9 5.9
0.1 0.1 0 0.1 0.1
19.8* 12.8 24.0* 17.7 27.8*
1.4* 1.2 2.0 1.7 3.6*
5.7* 4.0 7.5* 6.8 9.7*
14.5 16.4 15.8 22.0 20.1
3.2 4.6 3.9 8.1 9.5zatio
ing H
5 to 6
3,94
,940
9.0, 6
,238
,238
,238
,238
,940
,940
.7, 20
.1, 20
7.4, 1
, 6)
,884
,879nd 1
t 30
55 to
 3,9
inInfarction.
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March 24, 2009:1021–30 Age and Antithrombotic Therapy in NSTE-ACSeparin with GP IIb/IIIa inhibitors) were 11.7% versus
.6% (p  0.17), 4.2% versus 3.0% (p  0.20), 7.4% versus
.8% (p  0.19), and 2.2% versus 2.4% (p  0.74),
espectively. Similar results were observed for the compo-
ents of the ischemic end point in the other age categories,
nd among the PCI subgroup (Table 4). For patients 75
ears old in this last subgroup, the rates of composite
schemic outcomes, death, MI, and unplanned revascular-
zation at 30 days for the 2 different antithrombotic strate-
ies (bivalirudin alone vs. heparin with GP IIb/IIIa inhib-
tors) were 12.2% versus 11.0% (p  0.57), 3.2% versus
.6% (p  0.64), 8.1% versus 6.6% (p  0.37), and 3.2%
ersus 3.5% (p  0.77), respectively. For all the 30-day
schemic outcomes, the interaction between age and treat-
ent was not statistically significant. The overall 1-year
ortality and composite ischemic outcomes across all age
ategories were not statistically different between those
atients randomized to bivalirudin alone and those random-
zed to heparin plus GP IIb/IIIa inhibitors (Table 3).
leeding end point for overall and PCI groups. Major
leeding events increase with age (Table 3). The rates of
ajor bleeding in the age groups overall were 3.4%, 3.8%,
.7%, and 9.1%, for ages 55, 55 to 64, 65 to 74, and 75
ears, respectively. Bivalirudin was associated with less
ajor and minor bleeding in comparison to heparin with
P IIb/IIIa inhibitors regardless of age. Similar results were
bserved for the components of major bleeding, and among
he PCI subgroup (Table 4). The rates of major bleeding in
vents Rates (%) in Each Treatment per Age Category at 30 Days
Table 4 Events Rates (%) in Each Treatment per Age Category
Age <55 yrs
N  3,655 (%)
Age
N
Bivalirudin Heparin/GPI Bivalirud
30-day outcomes
Net clinical outcomes 8.6 10.0 10.8
Composite ischemia 7.0 6.5 8.7
Death from any cause 0.1 0.2 0.8
Myocardial infarction 5.5 4.9 6.4
Unplanned revascularization 2.5 2.4 3.9
Non-CABG major bleeding 1.7 4.3* 3.0
Intracranial 0 0 0.1
Retroperitoneal 0.3 0.8 0.1
Access site 0.9 2.0 0.7
Hemoglobin decrease 3 g/dl 0.6 1.4 1.0
Hemoglobin decrease 4 g/dl 0.4 0.8 0.9
Blood transfusion 0.7 1.5 0.9
Reoperation for bleeding 0 0 0.1
Non-CABG minor bleeding 12.6 19.5* 14.5
TIMI major bleeding 1.0 1.2 0.3
TIMI minor bleeding 3.1 4.3 2.9
1-year outcomes
Composite ischemia 17.7 15.2 17.6
Mortality 1.3 0.5 1.7
p  0.05. Net clinical outcome  composite ischemia and non-CABG major bleeding outcomes.
PCI  percutaneous coronary intervention; other abbreviations as in Table 3.hose patients who underwent PCI in the age groups were y.4%, 5.1%, 5.5%, and 11.8%, for ages 55, 55 to 64, 65 to
4, and 75 years, respectively. Using the Thrombolysis In
yocardial Infarction bleeding classification, bivalirudin
as also significantly associated with less major and minor
leeding in comparison to heparin and GP IIb/IIIa inhib-
tors among patients older than 75 years of age overall and
mong the PCI population (Table 4).
The rates of major bleeding in patients after excluding
hose with excess dosing was 2.7%, 3.6%, 4.5%, and 8.2%, in
he age groups, respectively. Among these patients, the rates
f major bleeding were significantly lower in those treated
ith bivalirudin alone when compared with those treated
ith heparin plus GP IIb/IIIa inhibitors. Similar results in
ates of major bleeding were observed in patients without
xcess dosing who underwent PCI: 3.4%, 4.9%, 5.2%, and
0.5%, by age group, respectively.
NT. The NNT in each age category given the absolute risk
eduction in major bleeding with bivalirudin alone versus
eparin plus GP IIb/IIIa inhibitors for overall and PCI groups
re shown in Figures 1A and 1B, respectively. Because the
bsolute risk reduction for major bleeding was greater in
hose patients age 75 years, the NNT was much smaller
23 to prevent 1 bleed) in this age category when compared
ith patients55 years old (NNT of 67 to prevent 1 bleed).
or the PCI cohort, the absolute risk reduction for major
leeding was even greater in the elderly (age75 years), and
he NNT to prevent 1 major bleed was just 16 (Fig. 1B),
imilarly lower than among younger patients (age 55
Year for PCI Patients
0 Days and 1 Year for PCI Patients
64 yrs
40 (%)
Age 65 to 74 yrs
N  3,783 (%)
Age >75 yrs
N  2,441 (%)
Heparin/GPI Bivalirudin Heparin/GPI Bivalirudin Heparin/GPI
11.6 11.8 14.1 17.4 20.2
7.1 8.6 9.4 12.2 11.0
1.0 1.0 0.5 3.2 2.6
4.9 6.5 6.6 8.1 6.6
2.5 3.5 4.5 3.2 3.5
5.7* 4.2 6.7* 6.1 12.3*
0 0 0.1 0 0
0.7 0.1 0.5 0.2 0.9
2.8* 1.5 3.0 0.7 6.4*
2.7* 1.1 2.7* 2.5 5.1*
0.7 1.1 1.2 1.4 1.3
2.8* 2.2 2.5 3.6 6.4
0.1 0.1 0 0.2 0
24.9* 14.4 28.7* 20.6 33.2*
2.0* 1.1 2.3 1.1 4.2*
6.7* 4.6 8.7* 7.5 11.6*
16.6 18.8 18.9 24.7 21.8
2.8 3.9 3.3 6.8 7.7and 1
at 3
55 to
 3,9
inears) at 38.
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ach age category given the absolute risk reduction in major
leeding with bivalirudin alone versus heparin plus GP
Ib/IIIa inhibitors among patients without excess dosing.
hese results are shown overall and for the PCI subgroup in
igures 2A and B. The absolute risk reduction for major
leeding was still greater in those age75 years treated with
ivalirudin alone, and the NNT was smaller (24) to prevent
bleed) in this age category when compared with patients
55 years old (NNT of 67). For the PCI cohort, the NNT
o prevent 1 major bleed in the elderly (age 75 years) was
5 (Fig. 2B), similarly lower than among younger patients
age 55 years) at 38.
ssociation between non-CABG major bleeding and
0-day and 1-year mortality. The 30-day and 1-year
ortality rates among those who did and did not experience
Figure 1
NNT With Bivalirudin Alone Versus
Heparin Plus GP IIb/IIIa Inhibitors to
Avoid 1 Non-CABG Major Bleeding Event
Data shown by age group and antithrombotic strategy. (A) The number needed
to treat (NNT) overall. (B) The NNT among percutaneous coronary intervention-
treated patients. CABG  coronary artery bypass graft; GPI  glycoprotein
inhibitor.non-CABG major bleeding event are shown by age inigure 3. Patients who experienced a non-CABG major
leed had significantly higher 30-day mortality rates when
ompared with those who did not (Fig. 3A). This was
onsistent across all 4 age categories. Similar patterns were
bserved for 1-year mortality rates across age (Fig. 3B).
iscussion
his analysis confirms no significant differences in efficacy
ut superior safety among patients randomized to a strategy
f bivalirudin alone compared with a strategy of heparin
lus a GP IIb/IIIa inhibitor across patient age. Further-
ore, it emphasizes that the absolute reduction in bleeding
vents is most pronounced in the oldest patient subgroup
age75 years), which then translates into the lowest NNT
n this age range. Among the oldest subgroup of patients,
he NNT with bivalirudin to prevent 1 major bleed overall
Figure 2
NNT With Bivalirudin Alone Versus Heparin Plus
GP IIb/IIIa Inhibitors to Avoid 1 Non-CABG Major
Bleeding Event Among Patients Without Excess Dose
Data shown by age group and antithrombotic strategy after excluding patients
who received excess dose of antithrombotic therapies (n  436) based on
renal function. (A) The NNT overall. (B) The NNT among percutaneous coronary
intervention-treated patients. Abbreviations as in Figure 1.
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espectively. This observation also persists in a subgroup in
hich patients who received excess dosing of antithrom-
otic therapies were eliminated. Thus, the lower rate of
leeding with bivalirudin alone reflects persisting differences
etween these strategies, and seems to be most relevant for
he oldest patients in whom standard pharmacotherapy
dvice has always been “start low, go slow.”
Aging is associated with an altered hemostatic state with
tendency toward increased bleeding in response to anti-
hrombotic agents (23). Hemostatic changes with aging
nclude increased anticoagulant proteins, clotting factors,
nd plasma viscosity. Aging also leads to diminished vascu-
ar response to injury because of impaired endothelial cell
egeneration capacity (24). At the same time, there is a
ecrease of regulatory proteins of endothelial cell origin
uch as nitric oxide, nitric oxide synthase, and prostacyclin,
nd a decrease in fibrinolytic capacity with age (25,26).
lder adults undergoing catheter-based interventions are at
dditional risk for bleeding because of the temporary loss of
Figure 3 Mortality Rates Among Patients With and
Without ACUITY Non-CABG Major Bleeding
Data shown by age group. (A) Rates of 30-day mortality. (B) Rates of 1-year
mortality. ACUITY  Acute Catheterization and Urgent Intervention Triage Strat-
egy; other abbreviations as in Figure 1.ascular integrity. Moreover, these age-related changes in ehe thrombotic milieu and capacity for vascular repair may
ead to different efficacy and safety of antithrombotic strat-
gies in older adults. In our study older adults had a lower
edian weight and similar rates of aspirin and thienopyri-
ine use compared with younger patients. Recently it was
hown that a higher body mass index is associated with
ower level of platelet inhibition (27). Therefore, a probable
ower body mass index among the elderly patients may have
ontributed to more platelet inhibition and played a role in
he higher bleeding rates among older adults.
In the ACUITY trial, approximately 18% of the patients
ere older than age 75 years, of whom 98% received a
ardiac catheterization and 56% were treated with a PCI.
hese numbers differ in terms of prevalence and invasive
are patterns from those observed in registries. In the
RACE (Global Registry of Acute Coronary Events) trial,
pproximately 25.7% of the patients were over 75 years of
ge, of whom 60% received a cardiac catheterization and
8% were treated with a PCI (28). Similarly, in the
RUSADE (Can Rapid Risk Stratification of Unstable
ngina Patients Suppress Adverse Outcomes With Early
mplementation of the American College of Cardiology/
merican Heart Association Guidelines) National Quality
mprovement Initiative, 35.5% of patients were older than
5 years of age, of whom 64% received a cardiac catheter-
zation, and 33% were treated with a PCI (29). These
umbers illustrate that findings from invasively managed
lder adults from clinical trials might have an even greater
mpact on practice considering the higher proportion of
lder patients in registries.
Despite the large number of antithrombotic strategy
tudies in NSTE-ACS (30 –38), these age-dependent
hanges in biology underscore the need for age-subgroup
nalyses that confirm safety and efficacy of specific anti-
hrombotic and antiplatelet regimens in patients with
STE-ACS. For example, the SYNERGY (Superior Yield
f the New Strategy of Enoxaparin, Revascularization and
lycoprotein IIb/IIIa Inhibitors) trial, which compared
noxaparin and unfractionated heparin for high-risk pa-
ients with NSTE-ACS (31), found no difference in the
ombined end point of 30-day death or MI between these
eparins. However, a subsequent pre-specified age-subgroup
nalysis showed a nonsignificant trend toward more bleed-
ng in older patients treated with enoxaparin (39). Similarly,
he PURSUIT (Platelet IIb/IIIa in Unstable angina: Re-
eptor Suppression Using Integrilin Therapy) trial showed a
ignificant reduction in 30-day death or MI in patients
reated with eptifibatide when compared with placebo, with
23% relative increase overall in moderate and severe
leeding (5). However, an age-subgroup analysis from
URSUIT showed that bleeding with eptifibatide was most
otable in those 80 years old, a subgroup that also
xperienced a 5.6% absolute and 23.6% relative increase in
eath or MI at 30 days with this strategy (40). The OASIS
(Fifth Organization to Assess Strategies in Acute Isch-mic Syndromes) trial randomized patients with NSTE-
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actor Xa inhibitor, was similar to enoxaparin in reducing
he risk of ischemic events, but with substantially less major
leeding. A subgroup analysis from the OASIS 5 trial in
atients with renal dysfunction, a common concern in
lderly patients, showed that the benefits of fondaparinux
ere most marked in patients with renal dysfunction,
rimarily because of lower rates of bleeding (42). The
SAR-REACT 3 (Intracoronary Stenting and Antithrom-
otic Regimen-Rapid Early Action for Coronary Treatment
) study randomized patients undergoing PCI with normal
roponin and pre-treatment with 600 mg of clopidogrel to
ivalirudin or unfractionated heparin (43). In this study, the
se of bivalirudin did not provide ischemic benefit when
ompared with UFH, but bivalirudin was associated with
ignificantly less bleeding. The present analysis from the
CUITY trial extends and magnifies these findings in the
ldest subgroup with NSTE-ACS undergoing an invasive
trategy.
Differences in antithrombotic safety may represent op-
ortunities to further optimize clinical outcomes in vulner-
ble patients, particularly when ischemic protection is un-
ompromised. We show that a strategy of bivalirudin alone
as associated with significantly lower rates of bleeding
hen compared with heparin plus GP IIb/IIIa inhibitors in
atients with NSTE-ACS. The significantly lower rates of
leeding in those who were older (age 75 years) translated
o the lowest NNT with bivalirudin to prevent 1 major
leed (23 overall and 16 if undergoing a PCI). Another
oncern is that comparisons of strategies should be based on
orrect delivery of agents based on weight and renal func-
ion. Excess dosing of antithrombotic agents occurs more
requently in clinical practice, particularly among older
atients (29). After excluding a relatively small number of
atients with excess dosing, elderly patients treated with a
trategy of bivalirudin alone continue to show less major
leeding compared with those treated with heparin plus GP
Ib/IIIa inhibitors. The NNT in this cohort of older
atients (age 75 years) to avoid 1 major bleeding was
early identical at 24 overall and 15 in those undergoing a
CI. In prior registry studies, the rates of excess dosing of
ntithrombotic agents were higher (20% to 35%) than noted
n the ACUITY trial population (44,45). This underscores
n additional difference between clinical trials and registries
n patient characteristics and management. Thus, the lower
ate of bleeding with the bivalirudin strategy might have an
ven greater impact in terms of bleeding reduction in a
eal-world setting where antithrombotic overdosing and
leeding are more prevalent than in the present study.
Current ACC/AHA guidelines emphasize that an inva-
ive strategy may be particularly beneficial for older adults
espite a higher risk of complications (9,28,46–48). Inter-
stingly, in a nonrandomized registry, invasive revascular-
zation procedures are associated with better 6-month out-
omes in the elderly (age 70 years) and very elderly (age
80 years) patients with NSTE-ACS (49), but concernver complications results in paradoxically lower rates of
CI among the elderly with NSTE-ACS (39). Bleeding,
hich is 3-fold higher in older adults, increases the long-
erm risk of death, stroke, and MI (3,12–15). In the present
tudy, we confirm higher 30-day and 1-year mortality
mong patients who experienced a non-CABG major bleed
ompared with those who did not across all age categories.
hile bleeding may be a surrogate for greater comorbidity
ay itself be an adverse clinical event, it is partly modifiable.
lthough the association between age and bleeding is
onfounded by lower creatinine clearance, anemia, and
emale sex, advanced age remains an independent predictor
f bleeding even after adjusting for the key baseline vari-
bles, in-hospital therapies, and invasive procedures (50).
herefore, the use of antithrombotic strategies that lessen
leeding complications are attractive options to optimize
he safety of care for older adults. Furthermore, superior
afety may also translate to clinical impact in the vulnerable
lderly for whom bleeding-associated prolonged length of
tay, anemia, and functional impairment are hazardous.
hus, a strategy of bivalirudin alone can preserve the
enefits of ischemic outcomes, and improve bleeding out-
omes in the elderly with NSTE-ACS.
onclusions
cross the spectrum of age, the use of bivalirudin alone is
ssociated with significantly lower rates of major bleeding
ompared with heparin plus a GP IIb/IIIa inhibitor in an
STE-ACS population treated with an invasive strategy.
ecause rates of bleeding increase with age, the benefit of
ivalirudin in terms of the NNT to prevent 1 bleeding event
s most notable for patients 75 years of age, especially
hose undergoing PCI. Importantly, the reduction in the
isk of bleeding with bivalirudin is not confined to older
atients and is seen in younger age groups (55, 55 to 64,
nd 64 to 74 years) as well. Superior bleeding outcomes for
he elderly may translate into shorter hospital stays and
mproved clinical outcomes.
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